Objective:

To address the integration and value of pharmacogenetic testing in clinical practice, focusing on overcoming barriers and enhancing clinical guidelines.

Approach:

• Task Force Establishment: A task force on pharmacogenetics was established to support the integration of pharmacogenetic testing into labs.
• Barriers Identification: Identified barriers include lack of access, missing clinical guidelines, and unclear reimbursement strategies.
• Evidence Presentation: Provided examples of pharmacogenetic testing benefits, including HLA-B*5701 for abacavir and CYP2D6 for tamoxifen.
• Collaboration Efforts: Established connections with organizations to support guideline implementation and answer questions.

Key Findings:

• 99% of individuals hypersensitive to abacavir test positive for HLA-B*5701.
• CYP2D6 testing shows that patients with deficient CYP2D6 have poorer outcomes on tamoxifen.
• CYP2C19 carriers with inactive alleles have increased risks associated with clopidogrel.

Interpretation:

Limitations:

• Existing barriers hinder the integration of pharmacogenetic testing.
• Clinical guidelines for some tests, like CYP2C19 for clopidogrel, are not yet implemented.

Conclusion:

The task force aims to secure the proper implementation of pharmacogenetics into patient care globally within two years by creating an international clinical laboratory network and ensuring high-quality testing.

Sources:

• Ron H. N. van Schaik